Since HMGB1 is overexpressed in breast cancer, TLR4 and AGER assessment offers a broader mechanistic perspective into innate immune activation and damage-associated inflammation, reinforcing the rationale for focusing on these markers. This evidence concerns the gene TLR4 and breast cancer.